Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
-0.12% $42.80
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 1 389.31 mill |
EPS: | -2.36 |
P/E: | -18.14 |
Earnings Date: | May 06, 2024 |
SharesOutstanding: | 32.46 mill |
Avg Daily Volume: | 0.302 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -18.14 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-3.09x |
Company: PE -18.14 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$10.26 (-76.02%) $-32.54 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 39.89 - 45.71 ( +/- 6.79%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-25 | Yen Kristen | Sell | 397 | Common Stock |
2024-01-25 | Hirano Patricia C | Sell | 832 | Common Stock |
2024-01-25 | Anish Bhatnagar | Sell | 2 527 | Common Stock |
2024-01-08 | Mario Ernest | Sell | 3 523 | Common Stock |
2024-01-04 | Yen Kristen | Buy | 24 000 | Common Stock |
INSIDER POWER |
---|
7.22 |
Last 99 transactions |
Buy: 11 445 959 | Sell: 9 863 264 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $42.80 (-0.12% ) |
Volume | 0.578 mill |
Avg. Vol. | 0.302 mill |
% of Avg. Vol | 191.24 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $46.91 | N/A | Active |
---|
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.